Also, Zhang and co-workers demonstrated in APPswe/PS1E9 mice that the Aβ42 peptide induces hepatic insulin resistance in vivo through the activation of the Janus Kinase 2 (JAK2), suggesting that inhibition of Aβ42 peptide production in the brain may be a novel strategy for the treatment of insulin resistance and therefore T2DM [73,74,75]. The gene discussed is JAK2; the disease is Insulin resistance.